These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 33471112

  • 1. TNFi-induced sustained clinical remission in peripheral spondyloarthritis patients cannot be maintained with a step-down strategy based on methotrexate.
    Carron P, De Craemer AS, Renson T, Colman R, Elewaut D, Van den Bosch F.
    Rheumatology (Oxford); 2021 Oct 02; 60(10):4880-4883. PubMed ID: 33471112
    [Abstract] [Full Text] [Related]

  • 2. Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.
    de Jong HMY, van Mens LJJ, Nurmohamed MT, Kok MR, van Kuijk AWR, Baeten DLP, van de Sande MGH.
    Arthritis Res Ther; 2019 Sep 14; 21(1):208. PubMed ID: 31521192
    [Abstract] [Full Text] [Related]

  • 3. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
    Vieira-Sousa E, Alves P, Rodrigues AM, Teixeira F, Tavares-Costa J, Bernardo A, Pimenta S, Pimentel-Santos FM, Gomes JL, Aguiar R, Pinto P, Videira T, Catita C, Santos H, Borges J, Sequeira G, Ribeiro C, Teixeira L, Ávila-Ribeiro P, Martins FM, Canhão H, McInnes IB, Ribeiro RM, Fonseca JE.
    Ann Rheum Dis; 2020 Apr 14; 79(4):490-498. PubMed ID: 32193187
    [Abstract] [Full Text] [Related]

  • 4. Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study.
    Carron P, Varkas G, Cypers H, Van Praet L, Elewaut D, Van den Bosch F, CRESPA investigator group.
    Ann Rheum Dis; 2017 Aug 14; 76(8):1389-1395. PubMed ID: 28213565
    [Abstract] [Full Text] [Related]

  • 5. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.
    van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, van Kuijk AWR, Baeten D.
    Ann Rheum Dis; 2019 May 14; 78(5):610-616. PubMed ID: 30808625
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC.
    Int J Rheum Dis; 2016 Nov 14; 19(11):1143-1156. PubMed ID: 26259617
    [Abstract] [Full Text] [Related]

  • 7. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.
    Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU.
    Arthritis Rheum; 2009 Aug 14; 60(8):2272-83. PubMed ID: 19644849
    [Abstract] [Full Text] [Related]

  • 8. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
    Nissen M, Delcoigne B, Di Giuseppe D, Jacobsson L, Hetland ML, Ciurea A, Nekvindova L, Iannone F, Akkoc N, Sokka-Isler T, Fagerli KM, Santos MJ, Codreanu C, Pombo-Suarez M, Rotar Z, Gudbjornsson B, van der Horst-Bruinsma I, Loft AG, Möller B, Mann H, Conti F, Yildirim Cetin G, Relas H, Michelsen B, Avila Ribeiro P, Ionescu R, Sanchez-Piedra C, Tomsic M, Geirsson ÁJ, Askling J, Glintborg B, Lindström U.
    Rheumatology (Oxford); 2022 Nov 28; 61(12):4741-4751. PubMed ID: 35323903
    [Abstract] [Full Text] [Related]

  • 9. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab.
    Taylor PC, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Mack M, Kremer J.
    J Rheumatol; 2011 Dec 28; 38(12):2572-80. PubMed ID: 22089463
    [Abstract] [Full Text] [Related]

  • 10. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
    Chang CY, Meyer RM, Reiff AO.
    Arthritis Care Res (Hoboken); 2015 May 28; 67(5):658-66. PubMed ID: 25220674
    [Abstract] [Full Text] [Related]

  • 11. Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis.
    G S Saad C, S R Silva M, Sampaio-Barros PD, C B Moraes J, G Schainberg C, Gonçalves CR, Shimabuco AY, Aikawa NE, F N Yuki E, G Pasoto S, V K Kupa L, K Aoyama R, S R Araujo C, Silva CA, Medeiros-Ribeiro AC, Bonfa E.
    Joint Bone Spine; 2023 Jan 28; 90(1):105464. PubMed ID: 36150668
    [Abstract] [Full Text] [Related]

  • 12. High Rate of Drug-Free Remission After Induction Therapy With Golimumab in Early Peripheral Spondyloarthritis.
    Carron P, Varkas G, Renson T, Colman R, Elewaut D, Van den Bosch F.
    Arthritis Rheumatol; 2018 Nov 28; 70(11):1769-1777. PubMed ID: 29806090
    [Abstract] [Full Text] [Related]

  • 13. Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
    Emery P, Fleischmann RM, Doyle MK, Strusberg I, Durez P, Nash P, Amante E, Churchill M, Park W, Pons-Estel B, Xu W, Xu S, Wu Z, Hsia EC.
    Arthritis Care Res (Hoboken); 2013 Nov 28; 65(11):1732-42. PubMed ID: 23861303
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.
    Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, Miyasaka N, Koike T, Baker D, Ishii Y, Yoshinari T, GO-FORTH study group.
    Mod Rheumatol; 2016 Jul 28; 26(4):481-90. PubMed ID: 26474192
    [Abstract] [Full Text] [Related]

  • 15. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK.
    Ann Rheum Dis; 2014 Oct 28; 73(10):1811-8. PubMed ID: 23897769
    [Abstract] [Full Text] [Related]

  • 16. Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study.
    Yonemoto Y, Okamura K, Takeuchi K, Ayabe K, Kaneko T, Matsushita M, Tamura Y, Iso T, Okura C, Otsuka K, Inoue H, Takagishi K.
    Mod Rheumatol; 2016 Oct 28; 26(1):24-8. PubMed ID: 26140464
    [Abstract] [Full Text] [Related]

  • 17. Effect of Secukinumab and Tumor Necrosis Factor Inhibitors on Humoral Response to BNT162b2 mRNA Vaccine in Patients With Spondyloarthritis Compared to Immunocompetent Controls.
    Eviatar T, Furer V, Polachek A, Zisman D, Peleg H, Elalouf O, Levartovsky D, Kaufman I, Broyde A, Haddad A, Feld J, Aassi M, Quebe-Fehling E, Alarcon I, Pel S, Paran D, Elkayam O.
    J Rheumatol; 2024 Apr 01; 51(4):415-422. PubMed ID: 37914221
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis: A retrospective study.
    Alegre-Sancho JJ, Juanola X, Rodríguez-Heredia JM, Manero J, Villa-Blanco I, Laiz A, Arteaga MJ, Cea-Calvo L, González CM.
    Medicine (Baltimore); 2021 Apr 02; 100(13):e25223. PubMed ID: 33787605
    [Abstract] [Full Text] [Related]

  • 19. The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study).
    Zhao J, Zhou W, Wu Y, Ji P, Yang L, Yan X, Zhang Z.
    BMC Med Inform Decis Mak; 2021 Mar 04; 21(1):83. PubMed ID: 33663487
    [Abstract] [Full Text] [Related]

  • 20. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
    Keystone EC, Genovese MC, Hall S, Miranda PC, Bae SC, Palmer W, Wu Z, Xu S, Hsia EC.
    J Rheumatol; 2013 Jul 04; 40(7):1097-103. PubMed ID: 23678153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.